Compare BBAR & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | SUPN |
|---|---|---|
| Founded | 1886 | 2005 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 1997 | 2010 |
| Metric | BBAR | SUPN |
|---|---|---|
| Price | $14.23 | $49.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.00 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 803.5K | 530.8K |
| Earning Date | 03-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $12.21 | $22.72 |
| Revenue Next Year | $13.00 | $18.10 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.76 | $29.16 |
| 52 Week High | $23.10 | $59.68 |
| Indicator | BBAR | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 42.81 |
| Support Level | $13.13 | $47.43 |
| Resistance Level | $17.36 | $52.14 |
| Average True Range (ATR) | 0.82 | 1.77 |
| MACD | 0.21 | -0.20 |
| Stochastic Oscillator | 53.28 | 35.23 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.